Suppression of growth of pre-existing tumors by intratumoral administration of AdNK4 and DCs.
(A) Colon-26 tumors, BALB/c mice. Colon-26 cells (2 × 105) were implanted subcutaneously in the right flank (day 0). On day 8, tumor-bearing mice were treated by intratumoral injection of 109 pfu of AdNK4, and 3 days later (day 11), tumors were inoculated with 2 × 105 DCs (▪). Alternatively, control mice were injected with AdNK4 followed by the day 11 administration of PBS instead of DCs (○) or injected with 109 pfu of AdNull followed by the day 11 inoculation of DCs (▵). (B) B16-F10 tumors, C57Bl/6 mice. This study was similar to that in panel A, but B16-F10 cells (3 × 105) were used. (C) 3LL-SA tumors, C57Bl/6 mice. This study was similar to that in panel A, but 3LL-SA cells (5 × 105) were used. (D) E.G7-OVA tumors, C57Bl/6 mice. This study was similar to that in panel A, but E.G7-OVA cells (2 × 105) were used. For all panels, the size of each tumor was assessed 3 times per week and is reported as the average tumor area (mm2) ± the standard error of n = 5 mice per group. Each experiment included tumor-bearing mice without any treatment as a control (■).
